This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes; obesity	Semaphorin 3E (SEMA3E); plexin D1 (PLXND1)	<p>Mouse studies suggest inhibiting SEMA3E could help treat obesity and diabetes. In a mouse model of diet-induced obesity, expression of Sema3e and its receptor, Plxnd1, was higher in adipose tissue than that seen in nondiabetic controls. In the mouse model, Sema3e inhibition with soluble Plxnd1 or with <i>Sema3e</i> knockout decreased adipose inflammation and insulin resistance compared with no inhibition or knockout. Next steps could include testing SEMA3E inhibition in additional animal models of diabetes.</p> <p>SciBX 6(44); doi:10.1038/scibx.2013.1257 Published online Nov. 14, 2013</p>	Patent and licensing status unavailable	<p>Shimizu, I. <i>et al. Cell Metab.</i>; published online Oct. 1, 2013; doi:10.1016/j.cmet.2013.09.001 Contact: Tohru Minamino, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan e-mail: t_minamino@yahoo.co.jp</p>